PYC pyc therapeutics limited

Ann: Strategic Partnership and Lead Program, page-17

  1. 2,359 Posts.
    lightbulb Created with Sketch. 775
    I agree, I don't like the spin off model, for that exact reason. Benefits can be hidden and diluted. Look at what happened with Phoremost. They got a lot of IP and we got Jack... That's not to say you don't ring fence risk through multiple entities, etc... that's just basic risk management...but spin-off's can be very bad for LT shareholders. As always, the devil is in the detail...which was not provided. That and the lack of $'s as part of the deal doesn't excite me as a shareholder. I like it, but it a ways off yet before there is a benefit. What did the market think of it?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.28
Change
0.010(0.79%)
Mkt cap ! $746.5M
Open High Low Value Volume
$1.27 $1.28 $1.27 $195.2K 153.8K

Buyers (Bids)

No. Vol. Price($)
1 13993 $1.27
 

Sellers (Offers)

Price($) Vol. No.
$1.28 6774 2
View Market Depth
Last trade - 13.40pm 27/06/2025 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.